Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Some Insurers Still Reluctant to Pay for New Biologic Drugs
Maui, Hawaii - Some insurers are reluctant to pay for the new biologic drugs for psoriasis, despite the approval of two of the drugs by the U.S. Food and Drug Administration, according to William Abramovits, M.D.
Related Videos
Related Content
